Effects of metformin therapy on the BG, Ins, PAI-1 and blood lipid levels in diabetic patients
10.3760/cma.j.issn.1673-4181.2015.03.010
- VernacularTitle:二甲双胍对糖尿病患者BG、Ins、PAI-1及血脂水平变化的影响分析
- Author:
Bo LIU
- Publication Type:Journal Article
- Keywords:
Metformin;
Diabetes;
Blood lipid;
Curative effect;
Blood glucose
- From:
International Journal of Biomedical Engineering
2015;(3):168-171
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of metformin on the blood glucose (BG), insulin (Ins), serum plasminogen activator inhibitor-1 (PAI-1) and blood lipid levels in diabetic patients. Methods Clinical data of 124 cases of diabetic patients admitted between Jan. 2010 and Dec. 2012 were retrospectively analyzed. The diabetic patients were randomly divided into the observation group (62 cases) and control group (62 cases). Patients in the observation group were treated with metformin, while the control group underwent Gliclazide sustained-release tablets treatment. Changes in BG, Ins, PAI-1 and blood lipid levels of the two groups were observed, and the contrast analysis was carried out. Results The BG, Ins and PAI-I levels of the observation group was significantly lower than that of the control group, and the differences were statistically significant (P<0.05).The cholesterol, triglyceride and low density lipoprotein cholesterol levels of patients in the observation group were significantly lower than that of the control group, and the differences were statistically significant (P<0.05). Standard deviation of NN intervals (SDNN), root mean square of successive differences (RMSSD) and percentage of adjacent NN intervals in a 24 hour recording which differ by at least 50 ms (PNN50) of the observation group were significantly higher than that of the control group, and the differences were statistically significant (P<0.05). Conclusions Metformin can effectively control the BG, Ins, PAI-1 and blood lipid levels of diabetic patient and improve the SDNN, RMSSD and PNN50, which is very favorable for the patients. Along with good safety, Metformin is suitable for clinical recommendation.
